

- [1] ADAM R, VINET E. Regional treatment of metastasis: surgery of colorectal liver metastases[J]. *Ann Oncol*, 2004, 15 Suppl 4: iv103-106.
- [2] SIEGEL R L, MILLER K D, GODING SAUER A, et al. Colorectal cancer statistics, 2020[J]. *CA Cancer J Clin*, 2020, 70(3): 145-164.
- [3] GIANNIS D, SIDERIS G, KAKOS C D, et al. The role of liver transplantation for colorectal liver metastases: A systematic review and pooled analysis[J]. *Transplant Rev (Orlando)*, 2020, 34(4): 100570.
- [4] TANIAI N, AKIMARU K, YOSHIDA H, et al. Surgical treatment for better prognosis of patients with liver metastases from colorectal cancer [J]. *Hepatogastroenterology*, 2007, 54(78): 1805-1809.
- [5] QIN S, LIU G J, HUANG M, et al. The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases; a review of a 4-year experience at a single center[J]. *Int J Hyperthermia*, 2019, 36(1): 36-43.
- [6] ARRU M, ALDRIGHETTI L, CASTOLDI R, et al. Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer[J]. *World J Surg*, 2008, 32(1): 93-103.
- [7] VIBERT E, CANEDO L, ADAM R. Strategies to treat primary unresectable colorectal liver metastases[J]. *Semin Oncol*, 2005, 32(6 Suppl 8): 33-39.
- [8] HONG Y S, SONG S Y, LEE S I, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer[J]. *Ann Oncol*, 2004, 15(9): 1344-1347.
- [9] STEWART C L, WARNER S, ITO K, et al. Cytorreduction for colorectal metastases; liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? [J]. *Curr Probl Surg*, 2018, 55(9): 330-379.
- [10] DE JONG M C, PULITANO C, RIBERO D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients[J]. *Ann Surg*, 2009, 250(3): 440-448.
- [11] GIULIANTE F, ARDITO F, VELLONE M, et al. Role of the surgeon as a variable in long-term survival after liver resection for colorectal metastases[J]. *J Surg Oncol*, 2009, 100(7): 538-545.
- [12] NORÉN A, SANDSTRÖM P, GUNNARSDOTTIR K, et al. Identification of inequalities in the selection of liver surgery for colorectal liver metastases in Sweden[J]. *Scand J Surg*, 2018, 107(4): 294-301.
- [13] MARGONIS G A, SERGENTANIS T N, NTANASIS-STATHOPOULOS I, et al. Impact of surgical margin width on recurrence and overall survival following R₀ hepatic resection of colorectal metastases: a systematic review and meta-analysis[J]. *Ann Surg*, 2018, 267(6): 1047-1055.
- [14] YANG A D, BROUQUET A, VAUTHEY J N. Extending limits of resection for metastatic colorectal cancer: risk benefit ratio[J]. *J Surg Oncol*, 2010, 102(8): 996-1001.
- [15] SHARMA S, CAMCI C, JABBOUR N. Management of hepatic metastasis from colorectal cancers: an update[J]. *J Hepatobiliary Pancreat Surg*, 2008, 15(6): 570-580.
- [16] TIMMERMAN R D, BIZEKIS C S, PASS H I, et al. Local surgical, ablative, and radiation treatment of metastases[J]. *CA Cancer J Clin*, 2009, 59(3): 145-170.
- [17] LV Y, FENG Q Y, WEI Y, et al. Benefits of multi-disciplinary treatment strategy on survival of patients with colorectal cancer liver metastasis[J]. *Clin Transl Med*, 2020, 10(3).
- [18] ADAM R, DE GRAMONT A, FIGUERAS J, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus[J]. *Cancer Treat Rev*, 2015, 41(9): 729-741.
- [19] BIPAT S, VAN LEEUWEN M S, IJZERMANS J N, et al. Evidence-base guideline on management of colorectal liver metastases in the Netherlands[J]. *Neth J Med*, 2007, 65(1): 5-14.
- [20] MONTEIL J, LE BRUN-LY V, CACHIN F, et al. Comparison of ¹⁸F-FDG-PET/CT and conventional follow-up methods in colorectal cancer: A randomised prospective study[J]. *Dig Liver Dis*, 2021, 53(2): 231-237.
- [21] GOURIET F, TISSOT-DUPONT H, CASALTA J P, et al. FDG-PET/CT incidental detection of cancer in patients investigated for infective endocarditis[J]. *Front Med (Lausanne)*, 2020, 7: 535.
- [22] COENEGRACHTS K, DE GEETER F, TER BEEK L, et al. Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases[J]. *Eur Radiol*, 2009, 19(2): 370-379.
- [23] JONES O M, REES M, JOHN T G, et al. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection[J]. *Br J Surg*, 2005, 92(9): 1165-1168.
- [24] KOSHARIYA M, JAGAD R B, KAWAMOTO J, et al. An update and our experience with metastatic liver disease[J]. *Hepatogastroenterology*, 2007, 54(80): 2232-2239.
- [25] KOMBOROZOS V A, SKREKAS G J, PISSIOTIS C A. The contribution of follow-up programs in the reduction of mortality of rectal cancer recurrences[J]. *Dig Surg*, 2001, 18(5): 403-408.
- [26] TSIKITIS V L, MALIREDDY K, GREEN E A, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial[J]. *J Clin Oncol*, 2009, 27(22): 3671-3676.
- [27] PFISTER D G, BENSON A B 3RD, SOMERFIELD M R.

- Clinical practice. Surveillance strategies after curative treatment of colorectal cancer[J]. *N Engl J Med*, 2004, 350(23): 2375-2382.
- [28] LOCKER G Y, HAMILTON S, HARRIS J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer[J]. *J Clin Oncol*, 2006, 24(33): 5313-5327.
- [29] DESCH C E, BENSON A B 3RD, SOMERFIELD M R, et al. Colorectal cancer surveillance; 2005 update of an American Society of Clinical Oncology practice guideline[J]. *J Clin Oncol*, 2005, 23(33): 8512-8519.
- [30] REX D K, KAHN C J, LEVIN B, et al. Guidelines for colonoscopy surveillance after cancer resection; a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer[J]. *CA Cancer J Clin*, 2006, 56(3): 160-167; quiz 185-166.
- [31] REX D K, KAHN C J, LEVIN B, et al. Guidelines for colonoscopy surveillance after cancer resection; a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer[J]. *Gastroenterology*, 2006, 130(6): 1865-1871.
- [32] MODEST D P, RICARD I, HEINEMANN V, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants; pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group[J]. *Ann Oncol*, 2016, 27(9): 1746-1753.
- [33] THERKILDSEN C, BERGMANN T K, HENRICHSEN-SCHNACK T, et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis[J]. *Acta Oncol*, 2014, 53(7): 852-864.
- [34] SCHIRRIPA M, CREMOLINI C, LOUPAKIS F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer[J]. *Int J Cancer*, 2015, 136(1): 83-90.
- [35] BRUDVIK K W, MISE Y, CHUNG M H, et al. RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases[J]. *Ann Surg Oncol*, 2016, 23(8): 2635-2643.
- [36] PASSOT G, CHUN Y S, KOPETZ S E, et al. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations[J]. *Eur J Surg Oncol*, 2016, 42(9): 1378-1384.
- [37] MARGONIS G A, BUETTNER S, ANDREATOS N, et al. Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases[J]. *Ann Surg*, 2017, 266(4): 641-649.
- [38] SORICH M J, WIESE M D, ROWLAND A, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials[J]. *Ann Oncol*, 2015, 26(1): 13-21.
- [39] MAO C, YANG Z Y, HU X F, et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis[J]. *Ann Oncol*, 2012, 23(6): 1518-1525.
- [40] KOPETZ S, GROTHEY A, YAEGER R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer[J]. *N Engl J Med*, 2019, 381(17): 1632-1643.
- [41] VAN CUTSEM E, HUIJBERTS S, GROTHEY A, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study[J]. *J Clin Oncol*, 2019, 37(17): 1460-1469.
- [42] GUREN T K, THOMSEN M, KURE E H, et al. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study[J]. *Br J Cancer*, 2017, 116(10): 1271-1278.
- [43] SINICROPE F A, SHI Q, ALLEGRA C J, et al. Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers: a secondary analysis of 2 randomized clinical trials[J]. *JAMA Oncol*, 2017, 3(4): 472-480.
- [44] PIKOULIS E, MARGONIS G A, ANDREATOS N, et al. Prognostic role of BRAF mutations in colorectal cancer liver metastases[J]. *Anticancer Res*, 2016, 36(9): 4805-4811.
- [45] MOREIRA L, BALAGUER F, LINDOR N, et al. Identification of Lynch syndrome among patients with colorectal cancer[J]. *Jama*, 2012, 308(15): 1555-1565.
- [46] UMAR A, BOLAND C R, TERDIMAN J P, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability[J]. *J Natl Cancer Inst*, 2004, 96(4): 261-268.
- [47] BUCHANAN D D, CLENDENNING M, ROSTY C, et al. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts[J]. *J Gastroenterol Hepatol*, 2017, 32(2): 427-438.
- [48] CHEN S, WATSON P, PARMIGIANI G. Accuracy of MSI testing in predicting germline mutations of MSH2 and MLH1: a case study in Bayesian meta-analysis of diagnostic tests without a gold standard[J]. *Biostatistics*, 2005, 6(3): 450-464.
- [49] HEMPELMANN J A, LOCKWOOD C M, KONNICK E Q, et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing[J]. *J Immunother Cancer*, 2018, 6(1): 29.
- [50] STELLOO E, JANSEN A M L, OSSE E M, et al. Practical

- guidance for mismatch repair-deficiency testing in endometrial cancer[J]. *Ann Oncol*, 2017, 28(1): 96-102.
- [51] MARSH S, HOSKINS J M. Irinotecan pharmacogenomics [J]. *Pharmacogenomics*, 2010, 11(7): 1003-1010.
- [52] BARBARINO J M, HAIDAR C E, KLEIN T E, et al. PharmGKB summary: very important pharmacogene information for UGT1A1 [J]. *Pharmacogenet Genomics*, 2014, 24(3): 177-183.
- [53] HOSKINS J M, GOLDBERG R M, QU P, et al. UGT1A1 *28 genotype and irinotecan-induced neutropenia: dose matters[J]. *J Natl Cancer Inst*, 2007, 99(17): 1290-1295.
- [54] GULER I, ASKAN G, KLOSTERGAARD J, et al. Precision medicine for metastatic colorectal cancer: an evolving era [J]. *Expert Rev Gastroenterol Hepatol*, 2019, 13(10): 919-931.
- [55] ALLGÄUER M, BUDCZIES J, CHRISTOPOULOS P, et al. Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians[J]. *Transl Lung Cancer Res*, 2018, 7(6): 703-715.
- [56] GONG J, CHEHRAZI-RAFFLE A, REDDI S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations[J]. *J Immunother Cancer*, 2018, 6(1): 8.
- [57] COCCO E, SCALTRITI M, DRILON A. NTRK fusion-positive cancers and TRK inhibitor therapy[J]. *Nat Rev Clin Oncol*, 2018, 15(12): 731-747.
- [58] ARTALE S, SARTORE-BIANCHI A, VERONESE S M, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer[J]. *J Clin Oncol*, 2008, 26(25): 4217-4219.
- [59] ETIENNE-GRIMALDI M C, FORMENTO J L, FRANCOUAL M, et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy[J]. *Clin Cancer Res*, 2008, 14(15): 4830-4835.
- [60] KNIJN N, MEKENKAMP L J, KLOMP M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients [J]. *Br J Cancer*, 2011, 104(6): 1020-1026.
- [61] OKUNO K. Surgical treatment for digestive cancer. Current issues - colon cancer[J]. *Dig Surg*, 2007, 24(2): 108-114.
- [62] BORSCHITZ T, WACHTLIN D, MÖHLER M, et al. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer[J]. *Ann Surg Oncol*, 2008, 15(3): 712-720.
- [63] READ T E, ANDUJAR J E, CAUSHAJ P F, et al. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status[J]. *Dis Colon Rectum*, 2004, 47(6): 825-831.
- [64] CHAU I, CHAN S, CUNNINGHAM D. Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives[J]. *Clin Colorectal Cancer*, 2003, 3(1): 19-33.
- [65] PEETERS K C, MARIJNEN C A, NAGTEGAAL I D, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma[J]. *Ann Surg*, 2007, 246(5): 693-701.
- [66] VAN GIJN W, MARIJNEN C A, NAGTEGAAL I D, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial[J]. *Lancet Oncol*, 2011, 12(6): 575-582.
- [67] KENNECKE H, LIM H, WOODS R, et al. Outcomes of unselected patients with pathologic T3N0 rectal cancer[J]. *Radiother Oncol*, 2012, 105(2): 214-219.
- [68] KLAUTKE G, FIETKAU R. Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review [J]. *Int J Colorectal Dis*, 2007, 22(5): 457-465.
- [69] MARTIJNSE I S, DUDINK R L, KUSTERS M, et al. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen [J]. *Ann Surg Oncol*, 2012, 19(2): 392-401.
- [70] SEBAG-MONTEFIORE D, STEPHENS R J, STEELE R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial [J]. *Lancet*, 2009, 373(9666): 811-820.
- [71] SIEGEL R, BUROCK S, WERNECKE K D, et al. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society[J]. *BMC Cancer*, 2009, 9: 50.
- [72] BUJKO K, WYRWICZ L, RUTKOWSKI A, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study [J]. *Ann Oncol*, 2016, 27(5): 834-842.
- [73] VERMAAS M, GOSSELINK M P, FERENSCHILD F T, et al. Introduction of preoperative radiotherapy in the treatment of operable rectal cancer in the Southwest region of the Netherlands[J]. *Eur J Surg Oncol*, 2007, 33(7): 862-867.
- [74] CERCEK A, ROXBURGH C S D, STROMBOM P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer[J]. *JAMA Oncol*, 2018, 4(6): e180071.
- [75] PETRELLI F, TREVISAN F, CABIDDU M, et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes[J]. *Ann Surg*, 2020, 271(3): 440-448.
- [76] XU J, ZHONG Y, WEIXIN N, et al. Preoperative hepatic and regional arterial chemotherapy in the prevention of liver

- metastasis after colorectal cancer surgery[J]. *Ann Surg*, 2007, 245(4): 583-590.
- [77] CHANG W, WEI Y, REN L, et al. Randomized controlled trial of intraportal chemotherapy combined with adjuvant chemotherapy (mFOLFOX6) for stage II and III colon cancer[J]. *Ann Surg*, 2016, 263(3): 434-439.
- [78] SUGIHARA K, OHTSU A, SHIMADA Y, et al. Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies[J]. *Clin Colorectal Cancer*, 2012, 11(2): 127-137.
- [79] RODRÍGUEZ-MORANTA F, SALÓ J, ARCUSA A, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial[J]. *J Clin Oncol*, 2006, 24(3): 386-393.
- [80] ANDRÉ T, BONI C, NAVARRO M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial[J]. *J Clin Oncol*, 2009, 27(19): 3109-3116.
- [81] KUEBLER J P, WIEAND H S, O'CONNELL M J, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07[J]. *J Clin Oncol*, 2007, 25(16): 2198-2204.
- [82] TVEIT K M, WIIG J N, OLSEN D R, et al. Combined modality treatment including intraoperative radiotherapy in locally advanced and recurrent rectal cancer[J]. *Radiother Oncol*, 1997, 44(3): 277-282.
- [83] YU T K, BHOSALE P R, CRANE C H, et al. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer[J]. *Int J Radiat Oncol Biol Phys*, 2008, 71(4): 1175-1180.
- [84] FENNELL M L, DAS I P, CLAUSER S, et al. The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality[J]. *J Natl Cancer Inst Monogr*, 2010, 2010(40): 72-80.
- [85] RABINOWITZ B. Interdisciplinary breast cancer care: declaring and improving the standard[J]. *Oncology (Williston Park)*, 2004, 18(10): 1263-1268; discussion 1268-1270, 1275.
- [86] NORDLINGER B, VAUTHEY J N, POSTON G, et al. The timing of chemotherapy and surgery for the treatment of colorectal liver metastases[J]. *Clin Colorectal Cancer*, 2010, 9(4): 212-218.
- [87] WRIGHT F C, DE VITO C, LANGER B, et al. Multidisciplinary cancer conferences: a systematic review and development of practice standards[J]. *Eur J Cancer*, 2007, 43(6): 1002-1010.
- [88] JUNG S M, HONG Y S, KIM T W, et al. Impact of a multidisciplinary team approach for managing advanced and recurrent colorectal cancer[J]. *World J Surg*, 2018, 42(7): 2227-2233.
- [89] DAVIES A R, DEANS D A, PENMAN I, et al. The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer[J]. *Dis Esophagus*, 2006, 19(6): 496-503.
- [90] FLEISSIG A, JENKINS V, CATT S, et al. Multidisciplinary teams in cancer care: are they effective in the UK? [J]. *Lancet Oncol*, 2006, 7(11): 935-943.
- [91] GABEL M, HILTON N E, NATHANSON S D. Multidisciplinary breast cancer clinics. Do they work? [J]. *Cancer*, 1997, 79(12): 2380-2384.
- [92] SCHIERGENS T S, VON EINEM J, THOMAS M N, et al. Multidisciplinary treatment of colorectal liver metastases [J]. *Minerva Med*, 2017, 108(6): 527-546.
- [93] CARTER S, GARSIDE P, BLACK A. Multidisciplinary team working, clinical networks, and chambers: opportunities to work differently in the NHS[J]. *Qual Saf Health Care*, 2003, 12 Suppl 1(Suppl 1): i25-28.
- [94] RUMMANS T A, CLARK M M, SLOAN J A, et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial[J]. *J Clin Oncol*, 2006, 24(4): 635-642.
- [95] DU C Z, LI J, CAI Y, et al. Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy[J]. *World J Gastroenterol*, 2011, 17(15): 2013-2018.
- [96] MACDERMID E, HOOTON G, MACDONALD M, et al. Improving patient survival with the colorectal cancer multidisciplinary team[J]. *Colorectal Dis*, 2009, 11(3): 291-295.
- [97] OBIAS V J, REYNOLDS H L, JR. Multidisciplinary teams in the management of rectal cancer[J]. *Clin Colon Rectal Surg*, 2007, 20(3): 143-147.
- [98] WANIS K N, PINEDA-SOLIS K, TUN-ABRAHAM M E, et al. Management of colorectal cancer with synchronous liver metastases: impact of multidisciplinary case conference review[J]. *Hepatobiliary Surg Nutr*, 2017, 6(3): 162-169.
- [99] LAN Y T, JIANG J K, CHANG S C, et al. Improved outcomes of colorectal cancer patients with liver metastases in the era of the multidisciplinary teams [J]. *Int J Colorectal Dis*, 2016, 31(2): 403-411.
- [100] LOOK HONG N J, GAGLIARDI A R, BRONSKILL S E, et al. Multidisciplinary cancer conferences: exploring obstacles and facilitators to their implementation [J]. *J Oncol Pract*, 2010, 6(2): 61-68.
- [101] BENTREM D J, DEMATTEO R P, BLUMGART L H. Surgical therapy for metastatic disease to the liver[J]. *Annu Rev Med*, 2005, 56: 139-156.
- [102] AKGÜL Ö, ÇETINKAYA E, ERSÖZ Ş, et al. Role of surgery in colorectal cancer liver metastases[J]. *World J Gastroenterol*, 2014, 20(20): 6113-6122.
- [103] MAYO S C, PAWLIK T M. Current management of color-

- ectal hepatic metastasis[J]. *Expert Rev Gastroenterol Hepatol*, 2009, 3(2): 131-144.
- [104] POSTON G J. Radiofrequency ablation of colorectal liver metastases; where are we really going? [J]. *J Clin Oncol*, 2005, 23(7): 1342-1344.
- [105] HUR H, KO Y T, MIN B S, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases[J]. *Am J Surg*, 2009, 197(6): 728-736.
- [106] REUTER N P, WOODALL C E, SCOGGINS C R, et al. Radiofrequency ablation vs. resection for hepatic colorectal metastasis; therapeutically equivalent? [J]. *J Gastrointest Surg*, 2009, 13(3): 486-491.
- [107] DEXIANG Z, LI R, YE W, et al. Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases[J]. *Ann Surg Oncol*, 2012, 19(9): 2860-2868.
- [108] KHAN A S, GARCIA-AROZ S, ANSARI M A, et al. Assessment and optimization of liver volume before major hepatic resection: Current guidelines and a narrative review[J]. *Int J Surg*, 2018, 52: 74-81.
- [109] BÉGIN A, MARTEL G, LAPOINTE R, et al. Accuracy of preoperative automatic measurement of the liver volume by CT-scan combined to a 3D virtual surgical planning software (3DVSP)[J]. *Surg Endosc*, 2014, 28(12): 3408-3412.
- [110] YAN TD, PADANG R, XIA H, et al. Management of involved or close resection margins in 120 patients with colorectal liver metastases; edge cryotherapy can achieve long-term survival[J]. *Am J Surg*, 2006, 191(6): 735-742.
- [111] BLAZER D G, 3RD, KISHI Y, MARU D M, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases[J]. *J Clin Oncol*, 2008, 26(33): 5344-5351.
- [112] JAECK D. The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies[J]. *Ann Surg Oncol*, 2003, 10(9): 1007-1011.
- [113] PULITANÒ C, BODINGBAUER M, ALDRIGHETTI L, et al. Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection[J]. *Ann Surg Oncol*, 2012, 19(2): 435-442.
- [114] MARGONIS G A, BUETTNER S, ANDREATOS N, et al. Prognostic factors change over time after hepatectomy for colorectal liver metastases: a multi-institutional, international analysis of 1 099 patients[J]. *Ann Surg*, 2019, 269(6): 1129-1137.
- [115] JAECK D, OUSSOULTZOGLOU E, ROSSO E. Hepatectomy for colorectal metastases in the presence of extrahepatic disease[J]. *Surg Oncol Clin N Am*, 2007, 16(3): 507-523, viii.
- [116] ADAM R, DE HAAS R J, WICHERTS D A, et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? [J]. *J Clin Oncol*, 2008, 26(22): 3672-3680.
- [117] ZIZZO M, GALEONE C, BRAGLIA L, et al. Long-term outcomes after surgical resection for synchronous or metachronous hepatic and pulmonary colorectal cancer metastases [J]. *Digestion*, 2020, 101(2): 144-155.
- [118] PULITANÒ C, BODINGBAUER M, ALDRIGHETTI L, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis[J]. *Ann Surg Oncol*, 2011, 18(5): 1380-1388.
- [119] TURRINI O, VIRET F, GUIRAMAND J, et al. Strategies for the treatment of synchronous liver metastasis[J]. *Eur J Surg Oncol*, 2007, 33(6): 735-740.
- [120] ZHAO D B, SHAN Y, WANG C F, et al. Surgical treatment for colorectal cancer with simultaneous hepatic metastasis[J]. *Zhonghua Zhong Liu Za Zhi*, 2007, 29(7): 552-554.
- [121] CHANG G J, KAISER A M, MILLS S, et al. Practice parameters for the management of colon cancer[J]. *Dis Colon Rectum*, 2012, 55(8): 831-843.
- [122] CAPUSSOTTI L, FERRERO A, VIGANÒ L, et al. Major liver resections synchronous with colorectal surgery[J]. *Ann Surg Oncol*, 2007, 14(1): 195-201.
- [123] NAKAJIMA K, TAKAHASHI S, SAITO N, et al. Predictive factors for anastomotic leakage after simultaneous resection of synchronous colorectal liver metastasis[J]. *J Gastrointest Surg*, 2012, 16(4): 821-827.
- [124] HATWELL C, BRETAGNOL F, FARGES O, et al. Laparoscopic resection of colorectal cancer facilitates simultaneous surgery of synchronous liver metastases[J]. *Colorectal Dis*, 2013, 15(1): e21-28.
- [125] SCHNITZBAUER A A, LANG S A, GOESSMANN H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings[J]. *Ann Surg*, 2012, 255(3): 405-414.
- [126] ROXBURGH C S, RICHARDS C H, MOUG S J, et al. Determinants of short- and long-term outcome in patients undergoing simultaneous resection of colorectal cancer and synchronous colorectal liver metastases[J]. *Int J Colorectal Dis*, 2012, 27(3): 363-369.
- [127] SLUPSKI M, WLODARCZYK Z, JASINSKI M, et al. Outcomes of simultaneous and delayed resections of synchronous colorectal liver metastases[J]. *Can J Surg*, 2009, 52(6): E241-244.
- [128] NANJI S, MACKILLOP W J, WEI X, et al. Simultaneous resection of primary colorectal cancer and synchronous liver metastases: a population-based study[J]. *Can J Surg*, 2017, 60(2): 122-128.
- [129] DE JONG M C, VAN DAM R M, MAAS M, et al. The liver-first approach for synchronous colorectal liver metastasis;

- a 5-year single-centre experience[J]. *HPB (Oxford)*, 2011, 13(10): 745-752.
- [130] DE JONG M C, BECKERS R C J, VAN WOERDEN V, et al. The liver-first approach for synchronous colorectal liver metastases: more than a decade of experience in a single centre[J]. *HPB (Oxford)*, 2018, 20(7): 631-640.
- [131] BROUQUET A, MORTENSON M M, VAUTHEY J N, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? [J]. *J Am Coll Surg*, 2010, 210(6): 934-941.
- [132] WAISBERG J, IVANKOVICS I G. Liver-first approach of colorectal cancer with synchronous hepatic metastases: A reverse strategy[J]. *World J Hepatol*, 2015, 7(11): 1444-1449.
- [133] ABBOTT D E, CANTOR S B, HU C Y, et al. Optimizing clinical and economic outcomes of surgical therapy for patients with colorectal cancer and synchronous liver metastases [J]. *J Am Coll Surg*, 2012, 215(2): 262-270.
- [134] KELLY M E, SPOLVERATO G, LÊ G N, et al. Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies[J]. *J Surg Oncol*, 2015, 111(3): 341-351.
- [135] PELOSI E, DEANDREIS D. The role of 18F-fluoro-deoxyglucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer[J]. *Eur J Surg Oncol*, 2007, 33(1): 1-6.
- [136] TOMLINSON J S, JARNAGIN W R, DEMATTEO R P, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure[J]. *J Clin Oncol*, 2007, 25(29): 4575-4580.
- [137] SHOUP M, GONEN M, DANGELICA M, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection[J]. *J Gastrointest Surg*, 2003, 7(3): 325-330.
- [138] SARPEL U, BONAVIA A S, GRUCELLA A, et al. Does anatomic versus nonanatomic resection affect recurrence and survival in patients undergoing surgery for colorectal liver metastasis? [J]. *Ann Surg Oncol*, 2009, 16(2): 379-384.
- [139] HAMMOND J S, GUHA I N, BECKINGHAM I J, et al. Prediction, prevention and management of postresection liver failure[J]. *Br J Surg*, 2011, 98(9): 1188-1200.
- [140] PAWLIK T M, SCOGGINS C R, ZORZI D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases[J]. *Ann Surg*, 2005, 241(5): 715-722, discussion 722-714.
- [141] AYEZ N, LALMAHOMED Z S, EGGERMONT A M, et al. Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy[J]. *Ann Surg Oncol*, 2012, 19(5): 1618-1627.
- [142] PANDANABOYANA S, WHITE A, PATHAK S, et al. Impact of margin status and neoadjuvant chemotherapy on survival, recurrence after liver resection for colorectal liver metastasis[J]. *Ann Surg Oncol*, 2015, 22(1): 173-179.
- [143] KOKUDO N, MIKI Y, SUGAI S, et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection[J]. *Arch Surg*, 2002, 137(7): 833-840.
- [144] ADAM R, MILLER R, PITOMBO M, et al. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases[J]. *Surg Oncol Clin N Am*, 2007, 16(3): 525-536, viii.
- [145] HASSELGREN K, SANDSTRÖM P, BJÖRNSSON B. Role of associating liver partition and portal vein ligation for staged hepatectomy in colorectal liver metastases: a review [J]. *World J Gastroenterol*, 2015, 21(15): 4491-4498.
- [146] BJÖRNSSON B, SPARRELID E, RÖSOK B, et al. Associating liver partition and portal vein ligation for staged hepatectomy in patients with colorectal liver metastases—Intermediate oncological results[J]. *Eur J Surg Oncol*, 2016, 42(4): 531-537.
- [147] ABBASI A, RAHNEMAI-AZAR A A, MERATH K, et al. Role of associating liver partition and portal vein ligation in staged hepatectomy (ALPPS)—strategy for colorectal liver metastases[J]. *Transl Gastroenterol Hepatol*, 2018, 3: 66.
- [148] BERTENS K A, HAWEL J, LUNG K, et al. ALPPS: challenging the concept of unresectability—a systematic review[J]. *Int J Surg*, 2015, 13: 280-287.
- [149] SPAMPINATO M G, MANDALÁ L, QUARTA G, et al. One-stage, totally laparoscopic major hepatectomy and colectomy for colorectal neoplasm with synchronous liver metastasis: safety, feasibility and short-term outcome[J]. *Surgery*, 2013, 153(6): 861-865.
- [150] RATTI F, SCHADDE E, MASETTI M, et al. Strategies to increase the resectability of patients with colorectal liver metastases: a multi-center case-match analysis of ALPPS and conventional two-stage hepatectomy[J]. *Ann Surg Oncol*, 2015, 22(6): 1933-1942.
- [151] FABER W, SEEHOFER D, NEUHAUS P, et al. Repeated liver resection for recurrent hepatocellular carcinoma[J]. *J Gastroenterol Hepatol*, 2011, 26(7): 1189-1194.
- [152] ADAM R, HOTI E, BREDDT L C. Evolution of neoadjuvant therapy for extended hepatic metastases—have we reached our (non-resectable) limit? [J]. *J Surg Oncol*, 2010, 102(8): 922-931.
- [153] KANZAKI R, HIGASHIYAMA M, ODA K, et al. Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma[J]. *Am J Surg*, 2011, 202(4): 419-426.
- [154] ELIAS D, BENIZRI E, POCARD M, et al. Treatment of synchronous peritoneal carcinomatosis and liver metastases

- from colorectal cancer[J]. *Eur J Surg Oncol*, 2006, 32(6): 632-636.
- [155] CARPIZO D R, DANGELICA M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease [J]. *Ann Surg Oncol*, 2009, 16(9): 2411-2421.
- [156] CLEARY J M, TANABE K T, LAUWERS G Y, et al. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver [J]. *Oncologist*, 2009, 14(11): 1095-1105.
- [157] TANAKA K, ADAM R, SHIMADA H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver [J]. *Br J Surg*, 2003, 90(8): 963-969.
- [158] LEONARD G D, BRENNER B, KEMENY N E. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma [J]. *J Clin Oncol*, 2005, 23(9): 2038-2048.
- [159] ADAMS R B, HALLER D G, ROH M S. Improving resectability of hepatic colorectal metastases; expert consensus statement by Abdalla et al [J]. *Ann Surg Oncol*, 2006, 13(10): 1281-1283.
- [160] BENOIST S, BROUQUET A, PENNA C, et al. Complete response of colorectal liver metastases after chemotherapy; does it mean cure? [J]. *J Clin Oncol*, 2006, 24(24): 3939-3945.
- [161] CHIAPPA A, BERTANI E, MAKUUCHI M, et al. Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases [J]. *Hepato-gastroenterology*, 2009, 56(91-92): 829-834.
- [162] FUJISAKI S, TAKASHINA M, SUZUKI S, et al. [Does complete response of liver metastases from colorectal cancer after chemotherapy mean cure?] [J]. *Gan To Kagaku Ryo-ho*, 2013, 40(12): 1662-1664.
- [163] GRUENBERGER B, SCHEITHAUER W, PUNZENGRUBER R, et al. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases [J]. *BMC Cancer*, 2008, 8: 120.
- [164] FOLPRECHT G, GROTHEY A, ALBERTS S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases; correlation between tumour response and resection rates [J]. *Ann Oncol*, 2005, 16(8): 1311-1319.
- [165] MENTHA G, MAJNO P, TERRAZ S, et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour [J]. *Eur J Surg Oncol*, 2007, 33 Suppl 2: S76-83.
- [166] NORDLINGER B, SORBYE H, GLIMELIUS B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial [J]. *Lancet*, 2008, 371(9617): 1007-1016.
- [167] ALOIA T, SEBAGH M, PLASSE M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases [J]. *J Clin Oncol*, 2006, 24(31): 4983-4990.
- [168] KAROUI M, PENNA C, AMIN-HASHEM M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases [J]. *Ann Surg*, 2006, 243(1): 1-7.
- [169] KATAOKA K, KANAZAWA A, NAKAJIMA A, et al. Feasibility and potential benefit of preoperative chemotherapy for colorectal liver metastasis (CLM): a single-centered retrospective study [J]. *Surg Today*, 2013, 43(10): 1154-1161.
- [170] MALIK H Z, FARID S, AL-MUKTHAR A, et al. A critical appraisal of the role of neoadjuvant chemotherapy for colorectal liver metastases: a case-controlled study [J]. *Ann Surg Oncol*, 2007, 14(12): 3519-3526.
- [171] STRAKA M, SKROVINA M, SOUMAROVA R, et al. Up front hepatectomy for metastatic rectal carcinoma - reversed, liver first approach. Early experience with 15 patients [J]. *Neoplasma*, 2014, 61(4): 447-452.
- [172] WELSH F K, TILNEY H S, TEKKIS P P, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing [J]. *Br J Cancer*, 2007, 96(7): 1037-1042.
- [173] FERNANDEZ F G, RITTER J, GOODWIN J W, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases [J]. *J Am Coll Surg*, 2005, 200(6): 845-853.
- [174] PAWLIK T M, OLINO K, GLEISNER A L, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome [J]. *J Gastrointest Surg*, 2007, 11(7): 860-868.
- [175] VAUTHEY J N, PAWLIK T M, RIBERO D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases [J]. *J Clin Oncol*, 2006, 24(13): 2065-2072.
- [176] GOMEZ D, MALIK H Z, BONNEY G K, et al. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis [J]. *Br J Surg*, 2007, 94(11): 1395-1402.
- [177] NAKANO H, OUSSOULTZOGLOU E, ROSSO E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy [J]. *Ann Surg*, 2008, 247(1): 118-124.
- [178] ADAM R, WICHERTS D A, DE HAAS R J, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases; myth or reality? [J]. *J Clin Oncol*, 2008, 26(10): 1635-1641.
- [179] HORGAN P G. Surgical management of disappearing colorectal liver metastases (Br J Surg 2013; 100: 1414-1420) [J].

- Br J Surg, 2013, 100(11): 1420.
- [180] VAN VLEDDER M G, DE JONG M C, PAWLIK T M, et al. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? [J]. J Gastrointest Surg, 2010, 14(11): 1691-1700.
- [181] ADAM R, DELVART V, PASCAL G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival[J]. Ann Surg, 2004, 240(4): 644-657; discussion 657-648.
- [182] BENOIST S, NORDLINGER B. Neoadjuvant treatment before resection of liver metastases [J]. Eur J Surg Oncol, 2007, 33 Suppl 2: S35-41.
- [183] POULTSIDES G A, SERVAIS E L, SALTZ L B, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment [J]. J Clin Oncol, 2009, 27(20): 3379-3384.
- [184] REDDY S K, BARBAS A S, CLARY B M. Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management? [J]. Ann Surg Oncol, 2009, 16(9): 2395-2410.
- [185] COSKUN U, BUYUKBERBER S, YAMAN E, et al. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients [J]. Neoplasma, 2008, 55(1): 65-70.
- [186] GRUENBERGER B, TAMANDL D, SCHUELLER J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26(11): 1830-1835.
- [187] MEHTA N N, RAVIKUMAR R, COLDHAM C A, et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases [J]. Eur J Surg Oncol, 2008, 34(7): 782-786.
- [188] PARKIN E, OREILLY D A, ADAM R, et al. The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy [J]. HPB (Oxford), 2013, 15(6): 463-472.
- [189] CLANCY T E, DIXON E, PERLIS R, et al. Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials [J]. J Gastrointest Surg, 2005, 9(2): 198-206.
- [190] KEMENY N, EID A, STOCKMAN J, et al. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma [J]. J Surg Oncol, 2005, 91(2): 97-101.
- [191] KEMENY N, JARNAGIN W, PATY P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer [J]. J Clin Oncol, 2005, 23(22): 4888-4896.
- [192] ANDRE T, BONI C, NAVARRO M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MO-SAIC trial [J]. J Clin Oncol, 2009, 27(19): 3109-3116.
- [193] KISHI Y, ZORZI D, CONTRERAS C M, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases [J]. Ann Surg Oncol, 2010, 17(11): 2870-2876.
- [194] BENOIST S, NORDLINGER B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases [J]. Ann Surg Oncol, 2009, 16(9): 2385-2390.
- [195] CHOTI M A. Chemotherapy-associated hepatotoxicity: do we need to be concerned? [J]. Ann Surg Oncol, 2009, 16(9): 2391-2394.
- [196] SAMANTAS E, DERVENIS C, RIGATOS S K. Adjuvant chemotherapy for colon cancer: evidence on improvement in survival [J]. Dig Dis, 2007, 25(1): 67-75.
- [197] ADAM R, BHANGUI P, POSTON G, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? [J]. Ann Surg, 2010, 252(5): 774-787.
- [198] SCHWARZ R E, BERLIN J D, LENZ H J, et al. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement [J]. HPB (Oxford), 2013, 15(2): 106-115.
- [199] VADEYAR H J. Current therapeutic options for colorectal liver metastases [J]. Indian J Gastroenterol, 2007, 26(1): 26-29.
- [200] DE GREEF K, ROLFO C, RUSSO A, et al. Multidisciplinary management of patients with liver metastasis from colorectal cancer [J]. World J Gastroenterol, 2016, 22(32): 7215-7225.
- [201] GOERE D, BENHAIM L, BONNET S, et al. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy [J]. Ann Surg, 2013, 257(1): 114-120.
- [202] HOUSE M G, KEMENY N E, GONEN M, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer [J]. Ann Surg, 2011, 254(6): 851-856.
- [203] KEMENY N E, JARNAGIN W R, CAPANU M, et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer [J]. J Clin Oncol, 2011, 29(7): 884-889.
- [204] ABDALLA E K. Commentary: Radiofrequency ablation for

- colorectal liver metastases; do not blame the biology when it is the technology[J]. *Am J Surg*, 2009, 197(6): 737-739.
- [205] FOLPRECHT G, GRUENBERGER T, BECHSTEIN W O, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab; the CELIM randomised phase 2 trial[J]. *Lancet Oncol*, 2010, 11(1): 38-47.
- [206] ADAM R. Chemotherapy and surgery; new perspectives on the treatment of unresectable liver metastases[J]. *Ann Oncol*, 2003, 14 Suppl 2: ii13-16.
- [207] GOLDBERG R M, SARGENT D J, MORTON R F, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer; a North American Intergroup Trial[J]. *J Clin Oncol*, 2006, 24(21): 3347-3353.
- [208] CALS L, RIXE O, FRANCOIS E, et al. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients[J]. *Ann Oncol*, 2004, 15(7): 1018-1024.
- [209] FALCONE A, RICCI S, BRUNETTI I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer; the Gruppo Oncologico Nord Ovest[J]. *J Clin Oncol*, 2007, 25(13): 1670-1676.
- [210] TOURNIGAND C, ANDRE T, ACHILLE E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer; a randomized GERCOR study[J]. *J Clin Oncol*, 2004, 22(2): 229-237.
- [211] HOCHSTER H S, HART L L, RAMANATHAN R K, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer; results of the TREE Study [J]. *J Clin Oncol*, 2008, 26(21): 3523-3529.
- [212] GOERE D, DESHAIES I, DE BAERE T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases[J]. *Ann Surg*, 2010, 251(4): 686-691.
- [213] MAHNKEN A H, PEREIRA P L, DE BAERE T. Interventional oncologic approaches to liver metastases[J]. *Radiology*, 2013, 266(2): 407-430.
- [214] NISHIOFUKU H, TANAKA T, ARAMAKI T, et al. Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy; a multicenter, retrospective analysis [J]. *Clin Colorectal Cancer*, 2010, 9(5): 305-310.
- [215] KABBINAVAR F F, SCHULZ J, MCCLEOD M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer; results of a randomized phase II trial[J]. *J Clin Oncol*, 2005, 23(16): 3697-3705.
- [216] SALTZ L B, CLARKE S, DIAZ-RUBIO E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer; a randomized phase III study[J]. *J Clin Oncol*, 2008, 26(12): 2013-2019.
- [217] VAN CUTSEM E, KÖHNE C H, HITRE E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. *N Engl J Med*, 2009, 360(14): 1408-1417.
- [218] FRAKER D L, SOULEN M. Regional therapy of hepatic metastases[J]. *Hematol Oncol Clin North Am*, 2002, 16(4): 947-967.
- [219] CIROCCHI R, TRASTULLI S, ABRAHA I, et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer[J]. *Cochrane Database Syst Rev*, 2012, (8): CD008997.
- [220] NITZKORSKI J R, FARMA J M, WATSON J C, et al. Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection[J]. *Ann Surg Oncol*, 2012, 19(2): 379-383.
- [221] COLUCCI G, GEBBIA V, PAOLETTI G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer; a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale[J]. *J Clin Oncol*, 2005, 23(22): 4866-4875.
- [222] NOREN A, ERIKSSON H G, OLSSON L I. Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study[J]. *Eur J Cancer*, 2016, 53: 105-114.
- [223] RUBBIA-BRANDT L, GIOSTRA E, BREZAULT C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery[J]. *Ann Oncol*, 2007, 18(2): 299-304.
- [224] YU Q, ZHANG L, FAN S, et al. The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases[J]. *J Cancer Res Ther*, 2016, 12(Supplement): C205-C211.
- [225] GHIRINGHELLI F, VINCENT J, BENGRIE L, et al. Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO); a randomized phase-II study [J]. *J Cancer Res Clin Oncol*, 2019, 145(9): 2357-2363.
- [226] KINDLER H L, SHULMAN K L. Metastatic colorectal cancer[J]. *Curr Treat Options Oncol*, 2001, 2(6): 459-471.
- [227] LIU Y, WU W, HONG W, et al. Raltitrexed-based chemotherapy for advanced colorectal cancer[J]. *Clin Res Hepatol*

- Gastroenterol, 2014, 38(2): 219-225.
- [228] ZELEK L, BUGAT R, CHERQUI D, et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial)[J]. *Ann Oncol*, 2003, 14(10): 1537-1542.
- [229] FAHY B N, D'ANGELICA M, DEMATTEO R P, et al. Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention[J]. *Ann Surg Oncol*, 2009, 16(2): 361-370.
- [230] PIESSEVAUX H, BUYSE M, SCHLICHTING M, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab[J]. *J Clin Oncol*, 2013, 31(30): 3764-3775.
- [231] SUZUKI C, BLOMQVIST L, SUNDIN A, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy[J]. *Ann Oncol*, 2012, 23(4): 948-954.
- [232] YE L C, WEI Y, ZHU D X, et al. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab[J]. *J Gastroenterol Hepatol*, 2015, 30(4): 674-679.
- [233] ALBERTS S R, HORVATH W L, STERNFELD W C, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study[J]. *J Clin Oncol*, 2005, 23(36): 9243-9249.
- [234] GIACCHETTI S, ITZHAKI M, GRUIA G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery[J]. *Ann Oncol*, 1999, 10(6): 663-669.
- [235] PERNOT S, ARTRU P, MITHIEUX F, et al. Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial[J]. *Clin Res Hepatol Gastroenterol*, 2015, 39(6): e73-77.
- [236] TANG W, REN L, LIU T, et al. Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME randomized controlled trial[J]. *J Clin Oncol*, 2020, 38(27): 3175-3184.
- [237] YE L C, LIU T S, REN L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases[J]. *J Clin Oncol*, 2013, 31(16): 1931-1938.
- [238] KARAPETIS C S, JONKER D, DANESHMAND M, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO. 17 [J]. *Clin Cancer Res*, 2014, 20(3): 744-753.
- [239] GARUFI C, TORSELLO A, TUMOLO S, et al. Cetuximab plus chromomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial[J]. *Br J Cancer*, 2010, 103(10): 1542-1547.
- [240] SOUGLAKOS J, ANDROULAKIS N, SYRIGOS K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)[J]. *Br J Cancer*, 2006, 94(6): 798-805.
- [241] CREMOLINI C, LOUPAKIS F, ANTONIOTTI C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study[J]. *Lancet Oncol*, 2015, 16(13): 1306-1315.
- [242] STEIN A, ATANACKOVIC D, HILDEBRANDT B, et al. Upfront FOLFOXIRI + bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer[J]. *Br J Cancer*, 2015, 113(6): 872-877.
- [243] TOMASELLO G, PETRELLI F, GHIDINI M, et al. FOLFOXIRI Plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis[J]. *JAMA Oncol*, 2017, 3(7): e170278.
- [244] ESIN E, YALCIN S. Maintenance strategy in metastatic colorectal cancer: A systematic review[J]. *Cancer Treat Rev*, 2016, 42: 82-90.
- [245] GOEY K K H, ELIAS S G, VAN TINTEREN H, et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study[J]. *Ann Oncol*, 2017, 28(9): 2128-2134.
- [246] HEGEWISCH-BECKER S, GRAEVEN U, LERCHENMULLER C A, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial[J]. *Lancet Oncol*, 2015, 16(13): 1355-1369.
- [247] SIMKENS L H, VAN TINTEREN H, MAY A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group [J]. *Lancet*, 2015, 385(9980): 1843-1852.
- [248] STEIN A, SCHWENKE C, FOLPRECHT G, et al. Effect

- of application and intensity of bevacizumab-based maintenance after induction chemotherapy with bevacizumab for metastatic colorectal cancer: a meta-analysis[J]. *Clin Colorectal Cancer*, 2016, 15(2): e29-39.
- [249] SONBOL M B, MOUNTJOY L J, FIRWANA B, et al. The role of maintenance strategies in metastatic colorectal cancer: a systematic review and network meta-analysis of randomized clinical trials[J]. *JAMA Oncol*, 2020, 6(3): e194489.
- [250] APARICIO T, GHIRINGHELLI F, BOIGE V, et al. Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9) [J]. *J Clin Oncol*, 2018, 36(7): 674-681.
- [251] XU R H, MURO K, MORITA S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial[J]. *Lancet Oncol*, 2018, 19(5): 660-671.
- [252] DUCREUX M, MALKA D, MENDIBOURE J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial[J]. *Lancet Oncol*, 2011, 12(11): 1032-1044.
- [253] KOOPMAN M, ANTONINI N F, DOUMA J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial[J]. *Lancet*, 2007, 370(9582): 135-142.
- [254] SEYMOUR M T, MAUGHAN T S, LEDERMANN J A, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial[J]. *Lancet*, 2007, 370(9582): 143-152.
- [255] GROTHEY A, VAN CUTSEME E, SOBRERO A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial[J]. *Lancet*, 2013, 381(9863): 303-312.
- [256] LI J, QIN S, XU R H, et al. Effect of fruquintinib *vs* placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial[J]. *JAMA*, 2018, 319(24): 2486-2496.
- [257] MAYER R J, VAN CUTSEME E, FALCONE A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer[J]. *N Engl J Med*, 2015, 372(20): 1909-1919.
- [258] SHITARA K, DOI T, DVORKIN M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. *Lancet Oncol*, 2018, 19(11): 1437-1448.
- [259] BENNOUNA J, BORG C, DELORD J P, et al. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study[J]. *Clin Colorectal Cancer*, 2012, 11(1): 38-44.
- [260] IWAMOTO S, HAZAMA S, KATO T, et al. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study[J]. *Anticancer Res*, 2014, 34(4): 1967-1973.
- [261] HURWITZ H, FEHRENBACHER L, NOVOTNY W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. *N Engl J Med*, 2004, 350(23): 2335-2342.
- [262] LE D T, URAM J N, WANG H, et al. PD-1 Blockade in Tumors with mismatch-repair deficiency[J]. *N Engl J Med*, 2015, 372(26): 2509-2520.
- [263] MARABELLE A, LE D T, ASCIERTO P A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study[J]. *J Clin Oncol*, 2020, 38(1): 1-10.
- [264] LE D T, DURHAM J N, SMITH K N, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. *Science*, 2017, 357(6349): 409-413.
- [265] YAGHOUBI N, SOLTANI A, GHAZVINI K, et al. PD-1/PD-L1 blockade as a novel treatment for colorectal cancer [J]. *Biomed Pharmacother*, 2019, 110: 312-318.
- [266] MERIC-BERNSTAM F, HURWITZ H, RAGHAV K P S, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study[J]. *Lancet Oncol*, 2019, 20(4): 518-530.
- [267] SARTORE-BIANCHI A, TRUSOLINO L, MARTINO C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial [J]. *Lancet Oncol*, 2016, 17(6): 738-746.
- [268] JIN Z, SINICROPE F A. Advances in the therapy of BRAF (V600E) metastatic colorectal cancer[J]. *Expert Rev Anticancer Ther*, 2019, 19(9): 823-829.
- [269] PRAHALLAD A, SUN C, HUANG S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR[J]. *Nature*, 2012, 483(7387): 100-103.
- [270] CHAN D L, ALZAHIRANI N A, MORRIS D L, et al. Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases[J]. *Surg Oncol*, 2015, 24(3): 162-171.

- [271] DANGELICA M I, CORREA-GALLEGO C, PATY P B, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes[J]. *Ann Surg*, 2015, 261(2): 353-360.
- [272] MCAULIFFE J C, QADAN M, DANGELICA M I. Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer[J]. *J Gastrointest Oncol*, 2015, 6(6): 699-708.
- [273] LEVY J, ZUCKERMAN J, GARFINKLE R, et al. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis[J]. *HPB (Oxford)*, 2018, 20(10): 905-915.
- [274] MINOCHA J, SALEM R, LEWANDOWSKI R J. Transarterial chemoembolization and yttrium-90 for liver cancer and other lesions[J]. *Clin Liver Dis*, 2014, 18(4): 877-890.
- [275] AMMORI J B, KEMENY N E, FONG Y, et al. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution[J]. *Ann Surg Oncol*, 2013, 20(9): 2901-2907.
- [276] MOCELLIN S, PASQUALI S, NITTI D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer[J]. *Cochrane Database Syst Rev*, 2009, (3): CD007823.
- [277] FELIBERTI E C, WAGMAN L D. Radiofrequency ablation of liver metastases from colorectal carcinoma [J]. *Cancer Control*, 2006, 13(1): 48-51.
- [278] HAMMILL C W, BILLINGSLEY K G, CASSERA M A, et al. Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases [J]. *Ann Surg Oncol*, 2011, 18(7): 1947-1954.
- [279] LIVRAGHI T, SOLBIATI L, MELONI M F, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study [J]. *Radiology*, 2003, 226(2): 441-451.
- [280] BERBER E, TSINBERG M, TELLIOGLU G, et al. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis[J]. *J Gastrointest Surg*, 2008, 12(11): 1967-1972.
- [281] BROUQUET A, ANDREOU A, VAUTHEY J N. The management of solitary colorectal liver metastases[J]. *Surgeon*, 2011, 9(5): 265-272.
- [282] KNUDSEN A R, KANNERUP A S, MORTENSEN F V, et al. Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy[J]. *Acta Radiol*, 2009, 50(7): 716-721.
- [283] SIPERSTEIN A E, BERBER E, BALLEM N, et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience[J]. *Ann Surg*, 2007, 246(4): 559-565; discussion 565-557.
- [284] RHIM H, LIM H K, KIM Y S, et al. Radiofrequency ablation of hepatic tumors: lessons learned from 3000 procedures [J]. *J Gastroenterol Hepatol*, 2008, 23(10): 1492-1500.
- [285] FACCIORUSSO A, DI MASO M, MUSCATELLO N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis[J]. *Int J Hyperthermia*, 2016, 32(3): 339-344.
- [286] XU Z, XIE H, ZHOU L, et al. The combination strategy of transarterial chemoembolization and radiofrequency ablation or microwave ablation against hepatocellular carcinoma[J]. *Anal Cell Pathol (Amst)*, 2019, 2019: 8619096.
- [287] ZHANG X, CHEN B, HU S, et al. Microwave ablation with cooled-tip electrode for liver cancer: an analysis of 160 cases[J]. *Hepatogastroenterology*, 2008, 55(88): 2184-2187.
- [288] GRUNDMANN R T, HERMANEK P, MERKEL S, et al. Diagnosis and treatment of colorectal liver metastases-workflow[J]. *Zentralbl Chir*, 2008, 133(3): 267-284.
- [289] SHONO Y, TABUSE K, TSUJI T, et al. Microwave coagulation therapy for unresectable colorectal metastatic liver tumor[J]. *Gan To Kagaku Ryoho*, 2002, 29(6): 856-859.
- [290] CHEN Y Y, PERERA D S, YAN T D, et al. Applying Fong's CRS liver score in patients with colorectal liver metastases treated by cryotherapy[J]. *Asian J Surg*, 2006, 29(4): 238-241.
- [291] SEIFERT J K, JUNGINGER T. Prognostic factors for cryotherapy of colorectal liver metastases[J]. *Eur J Surg Oncol*, 2004, 30(1): 34-40.
- [292] SEIFERT J K, JUNGINGER T. Cryotherapy for liver tumors: current status, perspectives, clinical results, and review of literature[J]. *Technol Cancer Res Treat*, 2004, 3(2): 151-163.
- [293] GIGNOUX B M, DUCERF C, MABRUT J Y, et al. Cryosurgery of primary and metastatic cancers of the liver[J]. *Ann Chir*, 2001, 126(10): 950-959.
- [294] AUSTIN-SEYMOUR M M, CHEN G T, CASTRO J R, et al. Dose volume histogram analysis of liver radiation tolerance[J]. *Int J Radiat Oncol Biol Phys*, 1986, 12(1): 31-35.
- [295] EBLE M J, GADEMANN G, WANNENMACHER M. [The value of radiotherapy for liver metastases][J]. *Strahlenther Onkol*, 1993, 169(8): 459-468.
- [296] YEO S G, KIM D Y, KIM T H, et al. Whole-liver radiotherapy for end-stage colorectal cancer patients with massive liver metastases and advanced hepatic dysfunction[J]. *Radiat Oncol*, 2010, 5: 97.
- [297] MOHIUDDIN M, CHEN E, AHMAD N. Combined liver radiation and chemotherapy for palliation of hepatic metastases

- ses from colorectal cancer[J]. *J Clin Oncol*, 1996, 14(3): 722-728.
- [298] RUSTHOVEN K E, KAVANAGH B D, CARDENES H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases[J]. *J Clin Oncol*, 2009, 27(10): 1572-1578.
- [299] COLLETTINI F, SCHNAPAUFF D, POELLINGER A, et al. Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates[J]. *Rofo*, 2012, 184(4): 316-323.
- [300] COMITO T, COZZI L, CLERICI E, et al. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach [J]. *BMC Cancer*, 2014, 14: 619.
- [301] TSELIS N, FERENTINOS K, KOLOTAS C, et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies[J]. *J Thorac Oncol*, 2011, 6(3): 545-552.
- [302] GOODMAN K A, WIEGNER E A, MATUREN K E, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies[J]. *Int J Radiat Oncol Biol Phys*, 2010, 78(2): 486-493.
- [303] KATZ A W, CAREY-SAMPSON M, MUHS A G, et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases[J]. *Int J Radiat Oncol Biol Phys*, 2007, 67(3): 793-798.
- [304] SCHEFTER T E, KAVANAGH B D, TIMMERMAN R D, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases[J]. *Int J Radiat Oncol Biol Phys*, 2005, 62(5): 1371-1378.
- [305] WOLPIN B M, MAYER R J. Systemic treatment of colorectal cancer[J]. *Gastroenterology*, 2008, 134(5): 1296-1310.
- [306] GROTHEY A, SUGRUE M M, PURDIE D M, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)[J]. *J Clin Oncol*, 2008, 26(33): 5326-5334.
- [307] WELCH S, SPITHOFF K, RUMBLE R B, et al. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review[J]. *Ann Oncol*, 2010, 21(6): 1152-1162.
- [308] TOL J, KOOPMAN M, CATS A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer [J]. *N Engl J Med*, 2009, 360(6): 563-572.
- [309] HECHT J R, MITCHELL E, CHIDIAC T, et al. A randomized phase III B trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer [J]. *J Clin Oncol*, 2009, 27(5): 672-680.
- [310] SPIGEL D R, GRECO F A, WATERHOUSE D, et al. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer [J]. *Clin Adv Hematol Oncol*, 2010, 8(7): 480-485, 498.
- [311] SATO Y, MATSUSAKA S, SUENAGA M, et al. Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients[J]. *Oncotargets Ther*, 2015, 8: 3329-3336.
- [312] BOKEMEYER C, BONDARENKO I, MAKHSON A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer[J]. *J Clin Oncol*, 2009, 27(5): 663-671.
- [313] WONG R, CUNNINGHAM D, BARBACHANO Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection[J]. *Ann Oncol*, 2011, 22(9): 2042-2048.
- [314] RAOUL J L, VAN LAETHEM J L, PEETERS M, et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study [J]. *BMC Cancer*, 2009, 9: 112.
- [315] VAN CUTSEM E, KÖHNE C H, LÁNG I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status[J]. *J Clin Oncol*, 2011, 29(15): 2011-2019.
- [316] PIETRANTONIO F, CREMOLINI C, PETRELLI F, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis[J]. *Crit Rev Oncol Hematol*, 2015, 96(1): 156-166.
- [317] DE ROOCK W, PIESSEVAUX H, DE SCHUTTER J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab[J]. *Ann Oncol*, 2008, 19(3): 508-515.
- [318] KARAPETIS C S, KHAMBATA-FORD S, JONKER D J, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer[J]. *N Engl J Med*, 2008, 359(17): 1757-1765.
- [319] AMADO R G, WOLF M, PEETERS M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer[J]. *J Clin Oncol*, 2008, 26(10): 1626-1634.
- [320] ROTH A D, TEJPAR S, DELORENZI M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial[J]. *J Clin Oncol*, 2010, 28(3): 466-474.
- [321] PRICE T J, HARDINGHAM J E, LEE C K, et al. Impact of KRAS and BRAF Gene mutation status on outcomes from

- the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer[J]. *J Clin Oncol*, 2011, 29(19): 2675-2682.
- [322] SARIDAKI Z, PAPADATOS-PASTOS D, TZARDI M, et al. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome[J]. *Br J Cancer*, 2010, 102(12): 1762-1768.
- [323] MAUGHAN T S, ADAMS R A, SMITH C G, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial[J]. *Lancet*, 2011, 377(9783): 2103-2114.
- [324] DOUILLARD J Y, SIENA S, CASSIDY J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study[J]. *J Clin Oncol*, 2010, 28(31): 4697-4705.
- [325] MCCORMACK L, PETROWSKY H, JOCHUM W, et al. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study[J]. *Ann Surg*, 2007, 245(6): 923-930.
- [326] VAN CUTSEM E, RIVERA F, BERRY S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study[J]. *Ann Oncol*, 2009, 20(11): 1842-1847.
- [327] LÓPEZ R, SALGADO M, REBOREDO M, et al. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer[J]. *Br J Cancer*, 2010, 103(10): 1536-1541.
- [328] CHAUDHURY P, HASSANAIN M, BOUGANIM N, et al. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis[J]. *HPB (Oxford)*, 2010, 12(1): 37-42.
- [329] CARTWRIGHT T H, YIM Y M, YU E, et al. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology[J]. *Clin Colorectal Cancer*, 2012, 11(4): 238-246.
- [330] HAMAMOTO Y, YAMAGUCHI T, NISHINA T, et al. A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study)[J]. *Oncologist*, 2014, 19(11): 1131-1132.
- [331] MASI G, SALVATORE L, BONI L, et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial[J]. *Ann Oncol*, 2015, 26(4): 724-730.
- [332] BENNOUNA J, PHELIP J M, ANDRÉ T, et al. Observational cohort study of patients with metastatic colorectal cancer initiating chemotherapy in combination with bevacizumab (CONCERT)[J]. *Clin Colorectal Cancer*, 2017, 16(2): 129-140. e124.
- [333] YIN C, MA G, RONG Y, et al. The efficacy of bevacizumab in different line chemotherapy for Chinese patients with metastatic colorectal cancer[J]. *J Cancer*, 2016, 7(13): 1901-1906.
- [334] DANGELICA M, KORNPAT P, GONEN M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study[J]. *Ann Surg Oncol*, 2007, 14(2): 759-765.
- [335] REDDY S K, MORSE M A, HURWITZ H I, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases[J]. *J Am Coll Surg*, 2008, 206(1): 96-106.
- [336] STARLINGER P, ALIDZANOVIC L, SCHAUER D, et al. Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation[J]. *Br J Cancer*, 2012, 107(6): 961-966.
- [337] SHITARA K, YAMANAKA T, DENDA T, et al. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients[J]. *Ann Oncol*, 2019, 30(2): 259-265.
- [338] LI J, QIN S, XU R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. *Lancet Oncol*, 2015, 16(6): 619-629.